EUVIMEDEUVIMED entdecken
Crossref

KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB–CD44–Akt signaling axis

Maha Alamodi Alghamdi, Hemali Deshpande, Ashish Kumar, Prasanna Rajagopalan

Medical Oncology · 2026

DOI: 10.1007/s12032-026-03377-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von Maha Alamodi Alghamdi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, College of Medicine, King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Enzyme Inhibitors, Signal Transduction, Triple Negative Breast Neoplasms. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Deanship of Scientific Research at King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kynureninase (KYNU), a hydrolase in tryptophan metabolism, has been implicated in cancer progression. However, the therapeutic relevance of targeting KYNU-mediated inflammatory signaling in triple-negative breast cancer (TNBC) remains poorly defined High-throughput virtual screening (HTVS) of the ChemBridge library, combined with protein-ligand interaction profiling, molecular dynamics simulations (GROMACS), and binding free energy analysis (GMX_MMPBSA), was employed to identify KYNU inhibitors. In vitro assays were performed in SUM159, MDA-MB-231, and HBL-100 cell lines. KS79356 was identified as the lead compound, displaying strong binding affinity (- 7.8 kcal/mol), stable interactions (RMSD ≈ 0.075 nm), and favorable binding free energy (ΔG = - 23.93 kcal/mol). KS79356 effectively inhibited KYNU activity (IC₅₀ = 63.7 nM) and selectively suppressed proliferation of SUM159 (GI₅₀ = 233 nM) and MDA-MB-231 (GI₅₀ = 450.8 nM) cells. Mechanistically, KS79356 downregulated TNF-α-induced activation of the NFκB-CD44-Akt signaling axis, leading to reduced proliferation, invasion, and trans-endothelial migration, while inducing both early and late apoptosis in TNBC cells. By targeting KYNU and attenuating the TNF-α/NFκB/CD44-Akt signaling axis, KS79356 demonstrates strong antitumor activity in TNBC. These findings highlight the novelty of KYNU as a therapeutic target and support the development of KS79356 as a potential treatment strategy for TNBC progression and metastasis.Clinical trial registrationNot applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsEnzyme InhibitorsSignal TransductionTriple Negative Breast NeoplasmsFemaleHumansApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionHyaluronan ReceptorsMDA-MB-231 CellsNF-kappa BProto-Oncogene Proteins c-aktTumor Necrosis Factor-alphaDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

CD44Kynureninase (KYNU)NFκBTriple-negative breast cancer (TNBC)p-Akt

Substanzen

Antineoplastic AgentsCD44 protein, humanEnzyme InhibitorsHyaluronan ReceptorsNF-kappa BProto-Oncogene Proteins c-aktTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Surgery, College of Medicine, King Khalid University, Abha, Saudi Arabia.
  • Department of Anatomy, College of Medicine, King Khalid University, Abha, Saudi Arabia.
  • Department of Microbiology & Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. prachu.rg@gmail.com.

Förderung

  • Deanship of Scientific Research at King Khalid University

Zitieren

APA

Alghamdi, M. A., Deshpande, H., Kumar, A., & Rajagopalan, P. (2026). KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB–CD44–Akt signaling axis. Medical Oncology. https://doi.org/10.1007/s12032-026-03377-5

Vancouver

Alghamdi MA, Deshpande H, Kumar A, Rajagopalan P. KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB–CD44–Akt signaling axis. Medical Oncology. 2026. doi:10.1007/s12032-026-03377-5

BibTeX
@article{Alghamdi2026,
  author = {Alghamdi, Maha Alamodi and Deshpande, Hemali and Kumar, Ashish and Rajagopalan, Prasanna},
  title = {KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB–CD44–Akt signaling axis},
  journal = {Medical Oncology},
  year = {2026},
  doi = {10.1007/s12032-026-03377-5}
}
Kostenlos starten →